​

Kyverna Therapeutics (KYTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

KYTX Stock Rating

Kyverna Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

KYTX Price Target Upside V Benchmarks

TypeNameUpside
StockKyverna Therapeutics-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.46$3.46$3.46
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2533---6
May, 25231--6
Apr, 25231--6
Mar, 25231--6
Feb, 25231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 27, 2025CitigroupPositiveupgrade
Oct 10, 2024UBSBuyinitialise
Oct 09, 2024Rodman & RenshawBuyinitialise
Sep 19, 2024H.C. WainwrightNeutralNeutralhold
Aug 15, 2024H.C. WainwrightNeutralNeutralhold
Jul 03, 2024H.C. WainwrightNeutralinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$-3.33----
Avg Forecast$-2.03$-3.30$-3.72$-3.62$-4.20$-4.35
High Forecast$-2.03$-3.15$-2.95$-1.59$-4.20$-4.35
Low Forecast$-2.03$-3.38$-4.29$-4.85$-4.20$-4.35
Surprise %-0.91%----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$3.75M$6.67M$12.50M--
High Forecast-$3.75M$6.67M$12.50M--
Low Forecast-$3.75M$6.67M$12.50M--
Surprise %------

Net Income Forecast

$-4B $-3B $-2B $-1B $-700M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-60.37M$-127.48M----
Avg Forecast$-1.37B$-2.20B$-2.44B$-2.17B$-2.83B$-2.93B
High Forecast$-1.37B$-2.12B$-1.99B$-1.07B$-2.83B$-2.93B
Low Forecast$-1.37B$-2.28B$-2.89B$-3.27B$-2.83B$-2.93B
Surprise %-95.58%-94.20%----

KYTX Forecast FAQ

Is Kyverna Therapeutics stock a buy?

Kyverna Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kyverna Therapeutics is a favorable investment for most analysts.

What is Kyverna Therapeutics's price target?

Kyverna Therapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $3.46.

How does Kyverna Therapeutics stock forecast compare to its benchmarks?

Kyverna Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Kyverna Therapeutics over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Kyverna Therapeutics’s EPS forecast?

Kyverna Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.72, marking a 11.71% increase from the reported $-3.33 in 2024. Estimates for the following years are $-3.62 in 2026, $-4.2 in 2027, and $-4.35 in 2028.

What is Kyverna Therapeutics’s revenue forecast?

Kyverna Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $6.67M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $12.5M, followed by $0 for 2027, and $0 for 2028.

What is Kyverna Therapeutics’s net income forecast?

Kyverna Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-2.44B, representing an 1813.75% increase from the reported $-127M in 2024. Projections indicate $-2.169B in 2026, $-2.829B in 2027, and $-2.928B in 2028.